FDA Approves RP1 (vusolimogene oderparepvec) with Nivolumab for Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has approved Replimune's oncolytic immunotherapy RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma that has progressed after anti-PD-1 therapy. This regulatory action follows a favorable advisory committee vote on the efficacy results from the IGNYTE trial.